Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/10/2026

1. TTD
2. ABNB
3. NET
4. TEAM
5. FROG
6. DV
7. TWLO
8. CART
9. SPY
10. U

Go back to Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
(AMEX: SKYED) Delayed: 2.50 --0 (-0%)
Previous Close $2.50    52 Week High $ 
Open $20.42    52 Week Low $ 
Day High $2.50    P/E N/A 
Day Low $2.50    EPS $ 
Volume 6,107